Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−24.74 M USD
0.00 USD
5.88 M
About Actuate Therapeutics, Inc.
Sector
CEO
Daniel M. Schmitt
Headquarters
Fort Worth
Website
Founded
2015
FIGI
BBG00NK7LK03
Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ACTU is 6.77 USD — it has decreased by −3.97% in the past 24 hours. Watch Actuate Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Actuate Therapeutics, Inc. stocks are traded under the ticker ACTU.
ACTU stock has fallen by −16.11% compared to the previous week, the month change is a −23.07% fall, over the last year Actuate Therapeutics, Inc. has showed a −31.48% decrease.
We've gathered analysts' opinions on Actuate Therapeutics, Inc. future price: according to them, ACTU price has a max estimate of 20.00 USD and a min estimate of 20.00 USD. Watch ACTU chart and read a more detailed Actuate Therapeutics, Inc. stock forecast: see what analysts think of Actuate Therapeutics, Inc. and suggest that you do with its stocks.
ACTU reached its all-time high on Aug 15, 2024 with the price of 10.16 USD, and its all-time low was 5.51 USD and was reached on Sep 25, 2024. View more price dynamics on ACTU chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ACTU stock is 16.48% volatile and has beta coefficient of 0.87. Track Actuate Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Actuate Therapeutics, Inc. there?
Yes, you can track Actuate Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Actuate Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ACTU net income for the last quarter is −5.97 M USD, while the quarter before that showed −6.57 M USD of net income which accounts for 9.15% change. Track more Actuate Therapeutics, Inc. financial stats to get the full picture.
No, ACTU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ACTU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Actuate Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.